CV Sciences seeing strong consumer response to Reserve Collection and Wellness Line of products
49 views Dec 20, 2022 CV Sciences CEO Joseph Dowling joined Steve Darling from Proactive to share news about the company that is specializing in hemp extracts and other natural ingredients for its products. Dowling talks more about the two divisions of the company and where they operate. He also addressed their Q3 financial numbers as well.
Dowling also shares details about the strong response the company is getting from its newest products including the PlusCBD Reserve Collection Softgels which is designed to support stress relief and relaxation.
CV Sciences CEO Joseph Dowling - Mainstreaming Cannabinoids
Seeking Alpha Jun 28, 2021
Cannabidiol (CBD) is one of the major cannabinoids found in cannabis. CV Sciences (OTCQB: CVSI) operates in two divisions: its Consumer Products side which focuses on CBD products for the consumer market and its Drug Development division - the first medical solution it's working on is a nicotine cessation product using synthetic nicotine and cannabidiol. CEO Joseph Dowling on getting CBD out of the hands of the DEA; dialoguing with FDA based on science and years of data. Strong regulatory environment will grow the industry, not restrict it. Using expertise from fish oil industry.“
It's a fair point. They will not be able to do anything with it , the cost of trying would be many times more than what the company is even worth. And it's no sure thing. No, it's a dead issue with a dead stock. IMO
News 
Market Data 
Discover 
AI
